Unveiling the role of <i>KRAS</i> in Chinese colorectal cancer patients: a positive influence on tumor mutational burden.

Transl Cancer Res · 2024 · PMC11483435 · PMID 39430843

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

KRAS mutation is a highly significant biomarker that has been reported in approximately 20% of NSCLC patients and 45% of CRC patients ( 38 , 39 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.